BioCentury
ARTICLE | Clinical News

Ralfinamide: Phase IIb/III started

April 6, 2009 7:00 AM UTC

Newron began the 12-week, double-blind, international Phase IIb/III SERENA trial to compare 160 and 320 mg of oral ralfinamide given once daily vs. placebo in about 400 patients. Upon completion, pati...